Germany’s Merck invests in immune-oncology in Switzerland
Merck KGaA’s corporate venture division has created an immune-oncology company based on a mixture of small and large molecule drugs, including Merck and Pfizer’s Bavencio (avelumab).
Archives for June 20, 2017
Brazilian plant to make Humira biosimilar in 'tobacco-based bioreactors'
A tobacco plant-based platform could make monoclonal antibodies up to 90% cheaper than mammalian systems, says Axis Biotec which is building a pilot plant in Brazil.
Patient deaths end Seattle Genetics leukaemia Phase III trial
Seattle Genetics announced it has discontinued its Phase III Cascade trial of Vadastuximab Talirine (SGN-CD33A) for the treatment of frontline acute myeloid leukaemia (AML), due to patient deaths.